Share: Share on Facebook Share on Twitter Share on LinkedIn I recommend visiting to read:%0A%0A {0} %0A%0A {1}
Life Sciences Golden Triangle Report Life Sciences Golden Triangle Report

Life Sciences: Golden Triangle Lab Report

Jamie Renison • 29/01/2024
Our latest Life Sciences Lab Report on the UK's Golden Triangle. The report External Link looks closely at investment volumes, leasing take up, lab supply and pipeline, and investment into life sciences real estate across Cambridge, Oxford and London. 
Q4 2023 Take-Up Statistics
  • Key deals cause a surge in Golden Triangle leasing activity, totalling 352,000 sq ft in Q4
  • This is more than double both the previous quarter and the five year quarterly average
  • Q4 brings the 2023 total to 925,000 sq ft – the highest annual volume since 2015
Evolving Demand and Supply
  • Leasing volumes remain restrained by the shortage of supply in Cambridge
  • New stock completing in Oxford and London has eased acute availability shortages
  • There is 3.1 million sq ft of life sciences space under construction across the Golden Triangle
  • 26% of supply under construction is pre-let or under offer
  • Occupier demand across the Golden Triangle remains robust
  • Prime headline rents in Cambridge are now at £70.00 psf, up 8% of Q3’s £65.00 psf
Investment Market Insights
  • Investment activity in the Golden Triangle picked up in Q4 2023 leading to an annual total of over £553 million
  • This reflects a significant drop versus previous years, with activity continuing to be impacted by higher interest rates
  • The visible pipeline of assets coming to market, or going under offer, suggests investment activity will pick up going into 2024
Venture Capital
  • Venture capital (VC) funding in 2023 was down 8% on the five-year average, but is expected to increase in 2024
  • Golden Triangle VC funding volumes totalled £2.14 billion in 2023
  • Early Stage VC raises were fewer in number but larger in size 

Read more in our latest quarterly report External Link or get in touch with a member of the team to discuss further.


GSK Completes Sale Of Strategic Life Sciences Development Site

Real estate services firm Cushman & Wakefield has advised GSK plc on the sale of the surplus development land that sits alongside its 1 million sq ft Research & Development (R&D) facility in Stevenage to UBS Asset Management and Reef Group. 


Life Science

Life Sciences Update: October 2022

Following extraordinary investment, expansion, and innovation in 2021, the life sciences industry is poised for further growth and consistent demand in the years ahead.
Sandy Romero • 26/10/2022
Life Sciences Real Estate Services
We help life science companies create flexible real estate strategies to attract and retain top talent, while managing efficiency and costs.
Learn More

Ready to talk?

Get in touch with one of our professionals.
With your permission we and our partners would like to use cookies in order to access and record information and process personal data, such as unique identifiers and standard information sent by a device to ensure our website performs as expected, to develop and improve our products, and for advertising and insight purposes.

Alternatively click on More Options and select your preferences before providing or refusing consent. Some processing of your personal data may not require your consent, but you have a right to object to such processing.

You can change your preferences at any time by returning to this site or clicking on Cookies.
Agree and Close
These cookies ensure that our website performs as expected,for example website traffic load is balanced across our servers to prevent our website from crashing during particularly high usage.
These cookies allow our website to remember choices you make (such as your user name, language or the region you are in) and provide enhanced features. These cookies do not gather any information about you that could be used for advertising or remember where you have been on the internet.
These cookies allow us to work with our marketing partners to understand which ads or links you have clicked on before arriving on our website or to help us make our advertising more relevant to you.
Agree All
Reject All